Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma

Figures & data

Figure 1. Flowchart showing exclusions and study population.

Table 1. Table of demographic and histological features of patients and tumours.

	n	%
Number of eligible patients	132
Age, median (range)	64	24-87 years
Sex
Men	62	47
Women	70	53
Histology
Clear cell renal carcinoma (ccRCC)	114	86
Papillary renal carcinoma	15	11
Chromophobe carcinoma	1	0,8
Other renal malignancy
Nephroblastoma	1	0,8
Carcinoma of the collecting duct	1	0,8
T-stage
stage T1−T2	58	44
stage T3−T4	74	56
N-stage
N0	118	89
N1	14	11
M-stage
M0	107	81
M1	25	19
Fuhrman Grade
grade 1−2	64	48
grade 3−4	63	48
Missing values	5	4
Operation type
Partial nephrectomy	18	14
Radical nephrectomy	114	86
ccRCC Patients N0M0 at the time of diagnosis
Number of eligible patients	88
No recurrence	62	71
Disease recurrence	26	29

Figure 2. ROC curve analysis. ROC curve analysis of S-TATI and P-CRP for overall mortality of RCC patients.

Figure 3. Distribution of S-TATI according to disease. Box plots displaying s-TATI distribution according to malignancy (a), tumour stage (b), nodal stage (c) and metastatic stage (d). Boxes show 25th, 50th and 75th percentiles, whiskers show 5th and 95th percentiles. Outliers are represented with circles while black stars represent extreme outliers. Figure (a) includes benign tumours, but other figures include only malignant tumours.

Table 2. Univariate and multivariate analyses of postoperative S-TATI, other prognostic factors and RCC overall survival.*

		UVA			MVA
Variable	Patients (n)	HR	95% CI	p	HR	95% CI	p
Sex
Female	62
Male	70	0.72	0.46−1.13	0.15
Patient age (years)	132	1.03	1.01−1.05	0.01	1.03	1.01−1,01	0.004
Postoperative s-TATI as continuous variable	132	1.01	1.00−1.01	0.02	1.01	1.00−1.01	0.03
Fuhrman grade
Grade 1−2	64
Grade 3−4	63	1.05	0.67−1.64	0.83
Lymph node involvement
N0	118
N1	14	4.66	2.48−8.75	<0.001	3.47	1.76−6.94	<0.001
Metastatic state
M0	107
M1	25	3.11	1.86−5.21	<0.001	2.49	1.36−4.58	0.003
T-stage
stage T1−T2	58
stage T3−T4	74	1.78	1.12−2.84	0.01	1.12	0.66−1.90	0.68

*Analyzed with the Cox hazard regression model.

HR: hazard ratio; CI: confidence interval; N0: no lymph node involvement; N1: positive lymph node involvement; M0: no metastasis; M1: metastatic lesions; T-stage: tumour stage.

Table 3. Univariate and multivariate analyses of postoperative S-TATI, other prognostic factors and RCC cancer-specific survival.*

		UVA			MVA
Variable	Patients (n)	HR	95% CI	p	HR	95% CI	p
Sex
Female	62
Male	70	0.75	0.41 − 1.40	0.37
Patient age (years)	132	1.01	0.98 − 1.03	0.69
Postoperative s-TATI as a continuous variable	132	1.01	1.00 − 1.02	0.004	1.01	1.00 − 1.02	0.004
Fuhrman grade
Grade 1 − 2	64
Grade 3 − 4	63	1.62	0.87 − 3.05	0.13
Lymph node involvement
N0	118
N1	14	6.42	3.11 − 13.22	< 0.001	3.15	1.48 − 6.72	0.003
Metastatic state
M0	107
M1	25	6.24	3.34 − 11.65	< 0.001	3.09	1.55 − 6.16	0.001
T-stage
Stage T1 − T2	58
Stage T3 − T4	74	5.78	2.42 − 13.82	< 0.001	3.36	1.31 − 8.64	0.012

*Cox regression.

HR: hazard ratio; CI: confidence interval.

Figure 4. Overall survival of 132 patients with renal cell carcinoma by concentration of postoperative s-TATI.

Figure 5. Overall survival of 136 patients with renal cell carcinoma by concentration of preoperative s-TATI.